Style | Citing Format |
---|---|
MLA | Amini MR, et al.. "The Effects of Policosanol Supplementation on Creatinine: A Systematic Review and Dose–Response Meta-Analysis of Randomized Controlled Trials." BMC Complementary Medicine and Therapies, vol. 25, no. 1, 2025, pp. -. |
APA | Amini MR, Majd SS, Salavatizadeh M, Djafari F, Askari G, Hekmatdoost A (2025). The Effects of Policosanol Supplementation on Creatinine: A Systematic Review and Dose–Response Meta-Analysis of Randomized Controlled Trials. BMC Complementary Medicine and Therapies, 25(1), -. |
Chicago | Amini MR, Majd SS, Salavatizadeh M, Djafari F, Askari G, Hekmatdoost A. "The Effects of Policosanol Supplementation on Creatinine: A Systematic Review and Dose–Response Meta-Analysis of Randomized Controlled Trials." BMC Complementary Medicine and Therapies 25, no. 1 (2025): -. |
Harvard | Amini MR et al. (2025) 'The Effects of Policosanol Supplementation on Creatinine: A Systematic Review and Dose–Response Meta-Analysis of Randomized Controlled Trials', BMC Complementary Medicine and Therapies, 25(1), pp. -. |
Vancouver | Amini MR, Majd SS, Salavatizadeh M, Djafari F, Askari G, Hekmatdoost A. The Effects of Policosanol Supplementation on Creatinine: A Systematic Review and Dose–Response Meta-Analysis of Randomized Controlled Trials. BMC Complementary Medicine and Therapies. 2025;25(1):-. |
BibTex | @article{ author = {Amini MR and Majd SS and Salavatizadeh M and Djafari F and Askari G and Hekmatdoost A}, title = {The Effects of Policosanol Supplementation on Creatinine: A Systematic Review and Dose–Response Meta-Analysis of Randomized Controlled Trials}, journal = {BMC Complementary Medicine and Therapies}, volume = {25}, number = {1}, pages = {-}, year = {2025} } |
RIS | TY - JOUR AU - Amini MR AU - Majd SS AU - Salavatizadeh M AU - Djafari F AU - Askari G AU - Hekmatdoost A TI - The Effects of Policosanol Supplementation on Creatinine: A Systematic Review and Dose–Response Meta-Analysis of Randomized Controlled Trials JO - BMC Complementary Medicine and Therapies VL - 25 IS - 1 SP - EP - PY - 2025 ER - |